BioMarin posts first $1 billion quarter, sets VOXZOGO PDUFA date for hypochondroplasiaNov 2Quarterly updateBiomarin Pharmaceutical Incvosoritide
BioMarin halts VOXZOGO development for Noonan syndrome in childrenSep 15RestructuringBiomarin Pharmaceutical Incvosoritide
BioMarin raises 2026 revenue and VOXZOGO guidance, discontinues BMN 401Aug 6Quarterly updateBiomarin Pharmaceutical Incvosoritide